All In Biotech

Free tool

FAERS Monitor: Incruse Ellipta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205382 or its brand name (Incruse Ellipta, Umeclidinium Bromide). Reports on generic versions are filed under their own applications.

Reports

9,060

Serious

4,828

53% of reports

Hospitalization

2,445

Death reported

661

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea1,437
  • drug ineffective781
  • cough735
  • asthma640
  • pneumonia578
  • wrong technique in device usage process547
  • chronic obstructive pulmonary disease420
  • fatigue392
  • product dose omission issue354
  • death344
  • wheezing341
  • headache334
  • off label use329
  • malaise327
  • nausea301

Reports by year received

View as table
YearReports
20101
20122
20132
20146
201599
2016636
2017870
20181,173
20191,241
20201,186
2021767
2022672
2023622
2024679
2025584
2026520

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,099 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
wrong technique in device usage processSignal54727.525.313,808
chronic obstructive pulmonary diseaseSignal42018.817.17,033
wheezingSignal34113.412.13,896
asthmaSignal64013.212.37,212
coughSignal7356.15.73,161
dyspnoeaSignal1,4375.95.65,997
pneumoniaSignal5784.23.81,398
product dose omission issueSignal3542.82.5412
malaise3271.71.6102
drug ineffective7811.41.385
headache3341.21.115
fatigue3921.21.110
death3440.90.82
nausea3010.90.85
off label use3290.90.86

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.